MX2023010340A - Anticuerpos monoclonales neutralizantes de virus bk. - Google Patents

Anticuerpos monoclonales neutralizantes de virus bk.

Info

Publication number
MX2023010340A
MX2023010340A MX2023010340A MX2023010340A MX2023010340A MX 2023010340 A MX2023010340 A MX 2023010340A MX 2023010340 A MX2023010340 A MX 2023010340A MX 2023010340 A MX2023010340 A MX 2023010340A MX 2023010340 A MX2023010340 A MX 2023010340A
Authority
MX
Mexico
Prior art keywords
virus
monoclonal antibodies
neutralizing monoclonal
antibodies
neutralizing
Prior art date
Application number
MX2023010340A
Other languages
English (en)
Inventor
Thomas M Moran
Thomas A Kraus
James A Duty
Domenico Tortorella
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of MX2023010340A publication Critical patent/MX2023010340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proveen anticuerpos monoclonales dirigidos a la VPI de poliomavirus que incluyen virus BK. También se proveen métodos para tratar o prevenir infecciones por poliomavirus usando uno o más anticuerpos.
MX2023010340A 2021-03-12 2022-03-11 Anticuerpos monoclonales neutralizantes de virus bk. MX2023010340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163160678P 2021-03-12 2021-03-12
PCT/US2022/020050 WO2022192740A1 (en) 2021-03-12 2022-03-11 Neutralizing monoclonal antibodies to bk virus

Publications (1)

Publication Number Publication Date
MX2023010340A true MX2023010340A (es) 2024-01-12

Family

ID=83228394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010340A MX2023010340A (es) 2021-03-12 2022-03-11 Anticuerpos monoclonales neutralizantes de virus bk.

Country Status (8)

Country Link
EP (1) EP4304650A1 (es)
JP (1) JP2024510976A (es)
KR (1) KR20240006505A (es)
CN (1) CN117615787A (es)
AU (1) AU2022232943A1 (es)
CA (1) CA3210390A1 (es)
MX (1) MX2023010340A (es)
WO (1) WO2022192740A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107752A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111902159A (zh) * 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
US11433132B2 (en) * 2017-12-01 2022-09-06 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
JP2024510976A (ja) 2024-03-12
KR20240006505A (ko) 2024-01-15
CA3210390A1 (en) 2022-09-15
EP4304650A1 (en) 2024-01-17
WO2022192740A1 (en) 2022-09-15
AU2022232943A9 (en) 2024-01-25
CN117615787A (zh) 2024-02-27
AU2022232943A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
MX2024006462A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
MX2022002682A (es) Anticuerpos anti-cd73.
EA201890447A1 (ru) Гуманизированные антитела к рецептору ccr7
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
PH12015502164A1 (en) Flavivirus neutralizing antibodies and methods of use thereof
EA202191629A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии pnpla3
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
MX2022014224A (es) Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
EA202191736A1 (ru) Комбинированная терапия hbv
MX2023001786A (es) Construcciones de iarn y metodos para inhibir la expresion de marc1.
EA202193296A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии scap, и способы их применения
EA201590111A1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202190647A1 (ru) Антитела к klrg1
MX2022014598A (es) Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
MX2024000563A (es) Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
EA201990613A1 (ru) Антитела против гремлина-1 (grem1) и способы их применения для лечения легочной артериальной гипертензии